Abstract
Since the introduction of dibenzepine (Noveril®) in the medical practice, this compound has been used for the management of depression. Stille et al. (1) have suggested that dibenzepine should be placed somewhere between imipramine and desipramine. In our laboratory we were engaged in an investigation on the influence of substitution on the tricyclic group on the biological activities of this type of compounds and found that the new compound, 5-methyl-8-ethylsulfonyl-10-(2-dimethylaminoethyl)-5H-dibenzo [b, e] [1, 4] diazepine-11 (10)-one (SM-307) was as potent as dibenzepine with regard to antagonism of reserpine induced hypothermia and had lower toxicity than dibenzepine. The present report serves to confirm some of the antidepressive effects of SM-307 compared with imipramine and other antidepressive substances.
